← Leaderboards
Aparna Raj Parikh
Massachusetts General Hospital
$1,079,955
Attributed
$1,079,955
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $271.3K · FY2022–25$500K$375K$250K$125K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,079,955 · 1
By mechanism
K08$1,079,955 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Andrew T Chan$39,910,857
- Daniel A. Haber$29,412,047
- Aaron N Hata$5,868,906
- Maha Farhat$7,486,819
- Richard T Liu$11,552,529
Others in their field
Other Rising Stars on “Early Identification”
- Heinz Ernst Moser · University Of Texas Med Br Galveston$13,657,841
- Jens Eickhoff · University Of Wisconsin-Madison$6,015,402
- Michele Caggana · Nysdoh/Health Research, Inc.$4,856,614
- Michael J Howell · University Of Minnesota$3,826,379
- Robert Pease Smith · Tufts University Boston$3,652,652
- Colin Osborne · University Of Texas Med Br Galveston$3,518,272
Research focus
Early IdentificationDoctor Of PhilosophyAdjuvant ChemotherapyAdvisory CommitteesBiological MarkersAdjuvantAdjuvant TherapyBiometryBloodCancer PatientCareerChemotherapyAdjuvant StudyClinical ApplicationClinical TrialsColon Cancer PatientsColon CarcinomaColorectal CancerDetectionDetection Of Minimal Residual DiseaseDisease-Free SurvivalDisease ProgressionDna AnalysisEarly Intervention
Grant awards (4)
Systematic liquid biopsy to monitor residual disease and treatment efficacy in gastrointestinal cancer patients$267,465
K08 · FY2025 · CA · contact PI
Systematic liquid biopsy to monitor residual disease and treatment efficacy in gastrointestinal cancer patients$271,298
K08 · FY2024 · CA · contact PI
Systematic liquid biopsy to monitor residual disease and treatment efficacy in gastrointestinal cancer patients$270,920
K08 · FY2023 · CA · contact PI
Systematic liquid biopsy to monitor residual disease and treatment efficacy in gastrointestinal cancer patients$270,272
K08 · FY2022 · CA · contact PI